{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:52:37Z","timestamp":1792450357004,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Immunology and Immunopathology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vetimm.2021.110322","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T15:57:11Z","timestamp":1630166231000},"page":"110322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["APB-F1, a long-acting feline granulocyte colony-stimulating factor fusion protein, created by exploiting FL335, a chimeric Fab specific for feline serum albumin"],"prefix":"10.1016","volume":"240","author":[{"given":"Hyun-jin","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-kyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-mi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3981-1399","authenticated-orcid":false,"given":"SeungGoo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-hyuk","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-hoon","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vetimm.2021.110322_bib0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bmt.1703136","article-title":"Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF) \u2013 results of a prospective randomised monocentre study","volume":"28","author":"B\u00f6nig","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.vetimm.2021.110322_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5326\/15473317-37-2-131","article-title":"Neutropenia in dogs and cats: a retrospective study of 261 cases","volume":"37","author":"Brown","year":"2001","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"10.1016\/j.vetimm.2021.110322_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.tvjl.2014.01.019","article-title":"Pegylated feline granulocyte colony-stimulating factor increases neutrophil levels in cats","volume":"200","author":"Coleman","year":"2014","journal-title":"Vet. J."},{"key":"10.1016\/j.vetimm.2021.110322_bib0020","first-page":"477","article-title":"Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV\/feline immunodeficiency virus (FIV)-coinfected symptomatic cats","volume":"18","author":"De Mari","year":"2004","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.vetimm.2021.110322_bib0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1098-612X(99)90004-9","article-title":"Cytokines and anti-cytokine therapy: clinical potential for treatment of feline disease","volume":"1","author":"Dunham","year":"1999","journal-title":"J. Feline Med. Surg."},{"key":"10.1016\/j.vetimm.2021.110322_bib0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/cyto.2001.0910","article-title":"Isolation, nucleotide sequence and expression of a cDNA encoding feline granulocyte colony-stimulating factor","volume":"14","author":"Dunham","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.vetimm.2021.110322_bib0035","series-title":"Biochemistry and Physiology of the Neutrophil","first-page":"6","author":"Edwards","year":"1994"},{"key":"10.1016\/j.vetimm.2021.110322_bib0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/9780470939932.ch14","article-title":"Purification of pegylated proteins","volume":"54","author":"Fee","year":"2011","journal-title":"Methods Biochem. Anal."},{"key":"10.1016\/j.vetimm.2021.110322_bib0045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tvjl.2006.08.001","article-title":"Granulocyte and granulocyte macrophage colony stimulating factors as therapy in human and veterinary medicine","volume":"174","author":"Fernandez-Varon","year":"2007","journal-title":"Vet. J."},{"key":"10.1016\/j.vetimm.2021.110322_bib0050","first-page":"37","article-title":"The immunogenicity of biologic therapies","volume":"53","author":"Garc\u00eas","year":"2018","journal-title":"Basel Karger"},{"key":"10.1016\/j.vetimm.2021.110322_bib0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijpharm.2005.06.007","article-title":"Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids","volume":"300","author":"Gregoriadis","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.vetimm.2021.110322_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-018-2491-5","article-title":"Quality comparison of biosimilar and copy filgrastim products with the innovator product","volume":"35","author":"Halim","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.vetimm.2021.110322_bib0065","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.vetimm.2021.110322_bib0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/nat.2016.0627","article-title":"A novel PEGylation method for improving the pharmacokinetic properties of anti-interleukin-17A RNA aptamers","volume":"27","author":"Haruta","year":"2017","journal-title":"Nucleic Acid Ther."},{"issue":"Supplement 1","key":"10.1016\/j.vetimm.2021.110322_bib0075","first-page":"4667","article-title":"Comparative cost-efficiency analysis of granulocyte colony-stimulating factors for use in chemotherapy patients in the United States","volume":"130","author":"James","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2021.110322_bib0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2019.01.009","article-title":"Intact bioactivities and improved pharmacokinetic of the SL335-IFN-\u03b2-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin Fab, and human interferon-\u03b2","volume":"207","author":"Ji","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.vetimm.2021.110322_bib0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2015.11.013","article-title":"Isolation of human anti-serum albumin Fab antibodies with an extended serum-half life","volume":"169","author":"Kang","year":"2015","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.vetimm.2021.110322_bib0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.imlet.2017.02.008","article-title":"Optimal expression of a Fab-effector fusion protein in Escherichia coli by removing the cysteine residues responsible for an interchain disulfide bond of a Fab molecule","volume":"184","author":"Kang","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.vetimm.2021.110322_bib0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jbiotec.2020.07.008","article-title":"Development of an integrated continuous PEGylation and purification process for granulocyte colony stimulating factor","volume":"322","author":"Kateja","year":"2020","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.vetimm.2021.110322_bib0100","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1016\/S0960-894X(02)00610-8","article-title":"Albumin affinity tags increase peptide half-life in vivo","volume":"12","author":"Koehler","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.vetimm.2021.110322_bib0105","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1074\/jbc.M700820200","article-title":"Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin","volume":"282","author":"Muller","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vetimm.2021.110322_bib0110","first-page":"129","article-title":"Preparation of competent cells for high-efficiency plasmid transformation of Escherichia coli","volume":"69","author":"Nakata","year":"1997","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"10.1016\/j.vetimm.2021.110322_bib0115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.vetimm.2005.06.010","article-title":"FIV-infected cats respond to short-term rHuG-CSF treatment which results in anti-G-CSF neutralizing antibody production that inactivates drug activity","volume":"108","author":"Phillips","year":"2005","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2021.110322_bib0120","series-title":"Molecular Cloning. A Laboratory Manual","author":"Sambrook","year":"1989"},{"key":"10.1016\/j.vetimm.2021.110322_bib0125","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.V74.4.1308.bloodjournal7441308","article-title":"Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation","volume":"74","author":"Schuening","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2021.110322_bib0130","first-page":"658","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"Am. Assoc. Pharmaceut. Scientists J."},{"key":"10.1016\/j.vetimm.2021.110322_bib0135","article-title":"Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates","volume":"12","author":"Shen","year":"2017","journal-title":"Public Library Sci. One"},{"key":"10.1016\/j.vetimm.2021.110322_bib0140","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.vetimm.2021.110322_bib0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.vetimm.2021.110322_bib0150","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.nano.2017.04.009","article-title":"Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting","volume":"13","author":"Tang","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.vetimm.2021.110322_bib0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0378-1119(01)00575-3","article-title":"Molecular cloning and expression of the cDNA encoding feline granulocyte colony-stimulating factor","volume":"274","author":"Yamamoto","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.vetimm.2021.110322_bib0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control. Release"}],"container-title":["Veterinary Immunology and Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242721001409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242721001409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:27:59Z","timestamp":1759044479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165242721001409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":32,"alternative-id":["S0165242721001409"],"URL":"https:\/\/doi.org\/10.1016\/j.vetimm.2021.110322","relation":{},"ISSN":["0165-2427"],"issn-type":[{"value":"0165-2427","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"APB-F1, a long-acting feline granulocyte colony-stimulating factor fusion protein, created by exploiting FL335, a chimeric Fab specific for feline serum albumin","name":"articletitle","label":"Article Title"},{"value":"Veterinary Immunology and Immunopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vetimm.2021.110322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110322"}}